| Source: HalifaxProj(inhibit) |
| Type: |
| Cyclooxygenase-2 (COX-2) is an enzyme that plays a critical role in the conversion of arachidonic acid to prostaglandins, which are lipid compounds involved in various physiological processes, including inflammation, pain, and fever. COX-2 is an inducible enzyme, meaning its expression is typically low in normal tissues but can be upregulated in response to inflammatory stimuli, growth factors, and certain oncogenic signals. -Cyclooxygenase-2 (COX-2), the rate-limiting enzyme in prostaglandin biosynthesis, plays a key role in inflammation and circulatory homeostasis. -COX-2 is an inducible enzyme that is upregulated in response to pro-inflammatory signals, including cytokines (e.g., IL-1β, TNF-α) and growth factors. COX-2 is often overexpressed in various tumors, including colorectal, breast, lung, and prostate cancers. The prostaglandins produced by COX-2, particularly prostaglandin E2 (PGE2), have several effects that can facilitate cancer progression: Cell Proliferation: PGE2 can promote the proliferation of cancer cells by activating signaling pathways such as the PI3K/Akt and MAPK pathways. Nonselective NSAIDs, such as aspirin and ibuprofen, inhibit both COX-1 and COX-2. Epidemiological studies have suggested that regular use of NSAIDs may reduce the risk of certain cancers, particularly colorectal cancer. Drugs specifically targeting COX-2, such as celecoxib, have been developed. COX-2 and xanthine oxidase are ROS-producing pro-oxidant enzymes that contribute to inflammation. Elevated COX‑2 levels, often found in inflammatory conditions or certain types of cancers, can contribute to increased production of ROS. |
| 1792- | CUR, | LEC, | Chondroprotective effect of curcumin and lecithin complex in human chondrocytes stimulated by IL-1β via an anti-inflammatory mechanism |
| - | in-vitro, | Arthritis, | RAW264.7 | - | NA, | NA, | HCC-38 |
| 1809- | CUR, | Oxy, | Long-term stabilisation of myeloma with curcumin |
| - | Case Report, | Melanoma, | NA |
| 1418- | CUR, | Potential complementary and/or synergistic effects of curcumin and boswellic acids for management of osteoarthritis |
| - | Review, | Arthritis, | NA |
| 1485- | CUR, | Chemo, | Rad, | Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs |
| - | Review, | Var, | NA |
| 6205- | CUR, | Clinical trials on curcumin in relation to its bioavailability and effect on malignant diseases: critical analysis |
| - | Review, | Var, | NA |
| 6211- | CUR, | The effect of curcumin on hypoxia in the tumour microenvironment as a regulatory factor in cancer |
| - | Review, | Var, | NA |
| 6214- | CUR, | Curcumin Nanoparticles-related Non-invasive Tumor Therapy, and Cardiotoxicity Relieve |
| 6215- | CUR, | Curcumin: biochemistry, pharmacology, advanced drug delivery systems, and its epigenetic role in combating cancer |
| - | Review, | Var, | NA |
| 6216- | CUR, | Role of Turmeric and Curcumin in Prevention and Treatment of Chronic Diseases: Lessons Learned from Clinical Trials |
| - | Review, | Var, | NA |
| 6212- | CUR, | Rad, | Radiosensitization and Radioprotection by Curcumin in Glioblastoma and Other Cancers |
| - | Review, | Var, | NA |
| 6223- | CUR, | Curcumin Rewires the Tumor Metabolic Landscape: Mechanisms and Clinical Prospects |
| - | Review, | Var, | NA |
| 6217- | CUR, | Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway |
| - | Review, | Var, | NA |
| 465- | CUR, | Curcumin inhibits the growth of liver cancer by impairing myeloid-derived suppressor cells in murine tumor tissues |
| - | vitro+vivo, | Liver, | HepG2 | - | vitro+vivo, | Liver, | HUH7 | - | vitro+vivo, | Liver, | MHCC-97H |
| 136- | CUR, | docx, | Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 158- | CUR, | Curcumin-targeting pericellular serine protease matriptase role in suppression of prostate cancer cell invasion, tumor growth, and metastasis |
| - | vitro+vivo, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 15- | CUR, | UA, | Effects of curcumin and ursolic acid in prostate cancer: A systematic review |
| - | Review, | Pca, | NA |
| 13- | CUR, | Role of curcumin in regulating p53 in breast cancer: an overview of the mechanism of action |
| - | Review, | BC, | NA |
| 160- | CUR, | Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2 |
| - | in-vitro, | Pca, | NA |
| 182- | CUR, | RES, | GI, | Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | LAPC-4 |
| 3753- | CUR, | Gala, | A Novel Galantamine–Curcumin Hybrid Inhibits Butyrylcholinesterase: A Molecular Dynamics Study |
| - | Study, | AD, | NA |
| 3795- | CUR, | Curcumin: A Golden Approach to Healthy Aging: A Systematic Review of the Evidence |
| - | Review, | AD, | NA |
| 3583- | CUR, | Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers |
| - | Review, | Arthritis, | NA |
| 3588- | CUR, | The effect of curcumin on cognition in Alzheimer’s disease and healthy aging: A systematic review of pre-clinical and clinical studies |
| - | Review, | AD, | NA |
| 3574- | CUR, | The effect of curcumin (turmeric) on Alzheimer's disease: An overview |
| - | Review, | AD, | NA |
| 2466- | CUR, | Regulatory Effects of Curcumin on Platelets: An Update and Future Directions |
| - | Review, | Nor, | NA |
| 2819- | CUR, | Chemo, | Curcumin as a hepatoprotective agent against chemotherapy-induced liver injury |
| - | Review, | Var, | NA |
| 2818- | CUR, | Novel Insight to Neuroprotective Potential of Curcumin: A Mechanistic Review of Possible Involvement of Mitochondrial Biogenesis and PI3/Akt/ GSK3 or PI3/Akt/CREB/BDNF Signaling Pathways |
| - | Review, | AD, | NA |
| 2814- | CUR, | Curcumin in Cancer and Inflammation: An In-Depth Exploration of Molecular Interactions, Therapeutic Potentials, and the Role in Disease Management |
| - | Review, | Var, | NA |
| 6238- | CUSP9, | A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3 |
| - | Trial, | GBM, | NA |
| - | NA, | GBM, | NA |
| 6683- | DCA, | Dichloroacetate for Cancer Treatment: Some Facts and Many Doubts |
| - | Review, | Var, | NA |
| 6701- | DFC, | Intracellular pH and calcium signaling as molecular targets of diclofenac-induced apoptosis against colon cancer |
| - | in-vivo, | Colon, | NA |
| 6702- | DFC, | Diclofenac |
| - | Review, | Nor, | NA |
| 6703- | DFC, | Molecular docking of anti-inflammatory drug diclofenac with metabolic targets: Potential applications in cancer therapeutics. |
| - | Analysis, | Var, | NA |
| 6705- | DFC, | Development and Challenges of Diclofenac-Based Novel Therapeutics: Targeting Cancer and Complex Diseases |
| - | Review, | Var, | NA |
| 6709- | DFC, | Diclofenac induced apoptosis via altering PI3K/Akt/MAPK signaling axis in HCT 116 more efficiently compared to SW480 colon cancer cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Colon, | SW480 |
| 6688- | DFC, | New Aspects of an Old Drug – Diclofenac Targets MYC and Glucose Metabolism in Tumor Cells |
| - | in-vivo, | lymphoma, | U937 |
| 6694- | DFC, | Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent |
| - | Review, | Var, | NA |
| 6692- | DFC, | Diclofenac Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer by Modulation of VEGF Levels and Arginase Activity |
| - | in-vivo, | PC, | Panc02 |
| 6663- | DFE, | Nutraceuticals of Phoenix dactylifera L.: Physicochemistry, Nutritional Value and Therapeutic Potential |
| - | Review, | Nor, | NA | - | Review, | AD, | NA |
| 6752- | DHA, | A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease |
| - | Trial, | BC, | NA |
| 1085- | DHA, | EPA, | DHA and EPA Down-regulate COX-2 Expression through Suppression of NF-kappaB Activity in LPS-treated Human Umbilical Vein Endothelial Cells |
| - | in-vitro, | Nor, | HUVECs |
| 6289- | DL, | D-Limonene modulates inflammation, oxidative stress and Ras-ERK pathway to inhibit murine skin tumorigenesis |
| - | in-vivo, | Var, | NA |
| 6282- | DL, | Limonene Exerts Anti-Inflammatory Effect on LPS-Induced Jejunal Injury in Mice by Inhibiting NF-κB/AP-1 Pathway |
| - | in-vivo, | IBD, | NA |
| 6281- | DL, | Applications of Limonene in Neoplasms and Non-Neoplastic Diseases |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Diabetic, | NA |
| 6317- | DRE, | The efficacy of dandelion root extract in inducing apoptosis in drug-resistant human melanoma cells |
| - | in-vitro, | Melanoma, | A375 |
| 6318- | DRE, | Dandelion root extract affects colorectal cancer proliferation and survival through the activation of multiple death signalling pathways |
| - | vitro+vivo, | CRC, | HCT116 | - | NA, | Nor, | NCM460 |
| 6363- | DRE, | Therapeutic Potential of Dandelion (Taraxacum officinale) Root Extract in Colon Cancer: A Comprehensive Review |
| - | in-vitro, | CRC, | NA |
| 1607- | EA, | Exploring the Potential of Ellagic Acid in Gastrointestinal Cancer Prevention: Recent Advances and Future Directions |
| - | Review, | GC, | NA |
| 1605- | EA, | Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:66 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid